News Column

New Antisense Technology Findings Reported from University of California (Screening the Role of Pronociceptive Molecules in a Rodent Model of...

August 21, 2014



New Antisense Technology Findings Reported from University of California (Screening the Role of Pronociceptive Molecules in a Rodent Model of Endometriosis Pain)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Biotechnology have been published. According to news reporting from San Francisco, California, by NewsRx journalists, research stated, "Chronic pain is a major symptom in patients with endometriosis, a common gynecologic condition affecting women in their reproductive years. Although many proalgesic substances are produced by endometriosis lesions, experimental evidence supporting their relative roles is still lacking."

The news correspondents obtained a quote from the research from the University of California, "Furthermore, it is unclear whether these proalgesic agents directly activate nociceptors to induce endometriosis pain. To determine their relative contribution to pain associated with endometriosis, we evaluated the intrathecal administration of oligodeoxynucleotides (ODNs) antisense to messenger RNA for receptors for 3 pronociceptive mediators known to be produced by the ectopic endometrium. Two weeks after the implant of autologous uterine tissue onto the gastrocnemius muscle, local mechanical hyperalgesia was observed in operated rats. Intrathecal antisense ODN targeting messenger RNA for the interleukin 6 receptor signaling complex subunit glycoprotein 130 and the nerve growth factor tyrosine kinase receptor A, but not their mismatch ODNs, reversibly attenuated mechanical hyperalgesia at the implant site. In contrast, intrathecal antisense ODN targeting the tumor necrosis factor receptor 1, at a dose that markedly inhibited intramuscularly injected tumor necrosis factor alpha, had only a small antihyperalgesic effect in this model. These results indicate the relative contribution of pronociceptive mediators produced by ectopic endometrial tissue to endometriosis pain. The experimental approach presented here provides a novel method to evaluate for the differential contribution of mediators produced by other painful lesions as well as endometriosis lesions as targets for novel treatment of pain syndromes. Perspective: This article presents evidence for the relative contribution of proalgesic mediators to primary hyperalgesia displayed by rats submitted to a model of endometriosis pain."

According to the news reporters, the research concluded: "This approach can be used to identify potential targets for the treatment of endometriosis pain."

For more information on this research see: Screening the Role of Pronociceptive Molecules in a Rodent Model of Endometriosis Pain. Journal of Pain, 2014;15(7):726-733. Journal of Pain can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Journal of Pain - www.elsevier.com/wps/product/cws_home/623147)

Our news journalists report that additional information may be obtained by contacting P. Alvarez, University of California, Div Neurosci, San Francisco, CA 94143, United States (see also Biotechnology).

Keywords for this news article include: Antisense Technology, Biotechnology, California, Hyperalgesia, San Francisco, United States, Endometriosis, Bioengineering, Women's Health, Sensation Disorders, Female Genital Diseases, Nervous System Diseases, Somatosensory Disorders, North and Central America, Neurologic Manifestations, Female Urogenital Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters